Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06691867 · ClinicalTrials.gov registry record · NA

Integrative Training Program for Pediatric Sickle Cell Pain

A NA study of Sickle Cell Disease, sponsored by Emory University.

Recruiting
Registry status
NA
Development phase
155
Enrollment target
4
Study locations

NCT06691867: Recruiting NA study of Sickle Cell Disease, sponsored by Emory University.

NCT06691867 is a NA study of Sickle Cell Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 155 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (47% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06691867, a NA study of Sickle Cell Disease, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
NA
Development phase
155 participants
Enrollment target
4
Study locations

Study Summary

This research aims to answer the question: does a group training program specifically for teens with chronic sickle cell disease (SCD) pain that teaches skills to strengthen the mind and body help improve everyday functioning and reduce pain symptoms? The program will be tailored to address challenges related to frequent or chronic sickle cell pain and may improve participants' physical and emotional health. The program, called I-STRONG for SCD (Integrative Strong Body and Mind Training for Sickle Cell Disease), may help improve everyday functioning and pain symptoms in teens with chronic pain related to SCD. The research team aims to determine how participants (teens and parents) respond to this program.

Primary Outcome

Pain intensity is rated with the pain severity item of the Brief Pain Inventory (BPI). The single item is scored on a scale from 0 to 10 where no pain = 0 and severe pain = 10. This outcome applies to teens only.

Conditions Studied

Sickle Cell Disease

Interventions

  • BEHAVIORAL I-STRONG
  • OTHER Enhanced Usual Care (EUC)

Study Locations (4)

Georgia

  • Children's Healthcare of Atlanta - Atlanta
  • Arthur M. Blank Hospital | Children's Healthcare of Atlanta - Atlanta

Connecticut

  • Connecticut Children's Medical Center - Hartford

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2025-01-08
Est. Completion 2027-08
Phase NA
Emory University

1,208 total trials

What NCT06691867 shows while recruiting

NCT06691867 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (47% lower).

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which I-STRONG is the first listed.

NCT06691867 reports a single indexed study location in Georgia, Connecticut, Ohio.

Frequently Asked Questions

What is clinical trial NCT06691867 about?

NCT06691867 is a clinical study titled "Integrative Training Program for Pediatric Sickle Cell Pain". This research aims to answer the question: does a group training program specifically for teens with chronic sickle cell disease (SCD) pain that teaches skills to strengthen the mind and body help improve everyday functioning and reduce pain symptoms? The program will be tailored to address challen...

What is the current status of trial NCT06691867?

This trial is currently recruiting. It is a NA study. The enrollment target is 155 participants. The study started on 2025-01-08. Estimated completion is 2027-08.

What conditions does trial NCT06691867 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT06691867?

The interventions under investigation include: I-STRONG (BEHAVIORAL), Enhanced Usual Care (EUC) (OTHER).

Who is sponsoring clinical trial NCT06691867?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06691867 being conducted?

This trial has 4 study locations across Connecticut, Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06691867's enrollment target sits among peer trials

155 44th of 213 higher than 170 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03223610 · 155 participants · Phase 1

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • NCT05072483 · 155 participants

    Natural History Study of CADASIL

  • NCT05086497 · 155 participants · NA

    WBSI Guided Personalized Delivery of TTFields

  • NCT05412069 · 155 participants · NA

    Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06691867

Source: ClinicalTrials.gov NCT06691867, the US trial registry maintained by the National Library of Medicine. NCT06691867 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.